Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst

Benzinga_recent_news12-05 04:38

Recent deaths of two patients with Duchenne muscular dystrophy (DMD) have opened the doors for emerging gene therapies, such as Solid Biosciences Inc's (NASDAQ:SLDB) SGT-003, according to Needham. The...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589780832?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/04/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-05 04:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589780832","market":"hk","top_or_hot":-1,"title":"Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst","media":"Benzinga_recent_news","content":"<div>\n<p>Recent deaths of two patients with Duchenne muscular dystrophy (DMD) have opened the doors for emerging gene therapies, such as Solid Biosciences Inc's (NASDAQ:SLDB) SGT-003, according to Needham.\nThe...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49219739/solid-biosciences-better-positioned-to-compete-in-dmd-gene-therapy-says-bullish-analyst\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSolid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-05 04:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49219739/solid-biosciences-better-positioned-to-compete-in-dmd-gene-therapy-says-bullish-analyst><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recent deaths of two patients with Duchenne muscular dystrophy (DMD) have opened the doors for emerging gene therapies, such as Solid Biosciences Inc's (NASDAQ:SLDB) SGT-003, according to Needham.\nThe...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49219739/solid-biosciences-better-positioned-to-compete-in-dmd-gene-therapy-says-bullish-analyst\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFTCPJ56.SGD","symbol_name":"Janus Henderson Global Life Sciences A Acc SGD","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49219739/solid-biosciences-better-positioned-to-compete-in-dmd-gene-therapy-says-bullish-analyst","article_id":"2589780832","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/04/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49219739/solid-biosciences-better-positioned-to-compete-in-dmd-gene-therapy-says-bullish-analyst","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589780832","pubTimestamp":1764880680,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price target, citing emerging gene therapies.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SRPT":"Sarepta Therapeutics","SLDB":"Solid Biosciences","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4112":"金融交易所和数据","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4139":"生物科技"},"translate_title":"乐观分析师表示，Solid Biosciences：在DMD基因治疗领域处于更有利的竞争地位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLDB":1.5,"SRPT":1},"content_text":"Recent deaths of two patients with Duchenne muscular dystrophy (DMD) have opened the doors for emerging gene therapies, such as Solid Biosciences Inc's (NASDAQ:SLDB) SGT-003, according to Needham.\nThe Solid Biosciences Analyst: Analyst Gil Blum initiated coverage with a Buy rating and price target of $16.\nThe Solid Biosciences Thesis: The company'sgene therapy SGT-003, which is \"designed to minimize liver toxicity without compromising on efficacy,\" is now better positioned in the DMD market after the efficacy of market leader Sarepta Therapeutics Inc's (NASDAQ:SRPT) gene therapy treatment Elevidys can been linked to two recent deaths, Blum said in the initiation note.\nCheck out other analyst stock ratings.\n\"Early results for SGT-003 show robust microdystrophin expression with no clinical signs of ALI despite a minimal immune suppressive regimen,\" he wrote.\nRegulatory updates in the first half of 2026 will determine if the approval of SGT-003 can be accelerated, which seems likely, the analyst stated. \"Initiation of Phase I studies in FA and CPVT are expected in 4Q:25 with potential for additional value creation in 2026,\" the analyst stated.\nSolid Biosciences' cash position, which was $268 million exiting the third quarter, seems to be sufficient to provide runway into the first half of 2027, he further said.\nSLDB Price Action: Shares of Solid Biosciences had risen by 10.98% to $5.76 at the time of publication on Wednesday.\nRead More:\nImage: Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589780832","isCrawlerRequest":true}